BioSpace News Archive

Business

Cytori Reports Third Quarter 2017 Business and Financial Results

Third quarter 2017 net loss was $4.8 million, or $0.14 per share.

November 10, 2017
·
12 min read
Business

Aileron Therapeutics Reports Third Quarter 2017 Financial Results

Cash, cash equivalents and investments as of September 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016.

November 10, 2017
·
11 min read
Business

BioCardia Reports Third Quarter 2017 Financial Results and Business Highlights

BioCardia reported a net loss of $3.0 million for the third quarter of 2017, which compares to a net loss of $3.3 million for the third quarter of 2016.

November 10, 2017
·
7 min read
Business

Skyline Medical Signs Distribution Agreement to Market STREAMWAY System in Australia and New Zealand

This distribution agreement is the latest milestone in our international expansion strategy, and follows the recent signing of partnerships with two independent distributors in Canada and Switzerland.

November 10, 2017
·
5 min read
Business

ICU Medical Announces Third Quarter 2017 Results

Third quarter 2017 revenue was $343.2 million, compared to $97.1 million in the same period last year.

November 10, 2017
·
21 min read
Business

Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update

Conference call and webcast scheduled for Friday, November 10 at 8:30am ET.

November 10, 2017
·
12 min read
Genetown

Seventure Partners Announces the Trade Sale of its Portfolio Company Cambrooke Therapeutics to Ajinomoto

Seventure Partners today announces the trade sale of its portfolio company Cambrooke Therapeutics, MA, US, to Ajinomoto.

November 10, 2017
·
1 min read
Genmab: Major Shareholder Announcement

BlackRock has increased their indirect ownership in Genmab to 3,076,324 shares, which amounts to 5.03% of the share capital and voting rights in Genmab.

November 10, 2017
·
3 min read
Policy

NVHR Welcomes FDA Approval of New Hepatitis B Vaccine

The NVHR today welcomed the FDA approval of HEPLISAV-B for prevention of hepatitis B virus infection in adults ages 18 and older.

November 10, 2017
·
2 min read
Business

Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance

Cash and cash equivalents as of September 30, 2017 were approximately $5.7 million compared to approximately $11.4 million as of December 31, 2016.

November 10, 2017
·
6 min read